nalmefene


Also found in: Dictionary, Wikipedia.

nalmefene

 [nal´mĕ-fēn″]
an opioid antagonist, used as the hydrochloride salt in the treatment of opioid overdose and postoperative opioid depression.

nalmefene

/nal·me·fene/ (nal´mĕ-fēn″) an opioid antagonist, used as the hydrochloride salt in the treatment of opioid overdose and postoperative opioid depression.

nalmefene

(năl′mə-fēn′)
n.
A drug, C21H25NO3, used as an antagonist to narcotic drugs.

nalmefene

[nal′mĕfēn′]
an opioid antagonist, used as the hydrochloride salt in the treatment of opioid overdose and postoperative opioid depression.

nalmefene, nalmetrene

a narcotic antagonist, similar to naloxone, used to temporarily control obsessive behavior such as crib-biting in horses and self-mutilation in dogs.
Mentioned in ?
References in periodicals archive ?
Nalmefene has a partial agonist effect on the kappa opioid receptors, but with a kappa receptor system in up-regulation as a result of chronic drinking it acts as a functional antagonist (Keating, 2013; Kisler, Sirohhi, Reis, Jansen, Quock et al.
In addition, the nalmefene tablet may be taken only when needed, while existing treatments have to be taken over a longer period of time to maintain abstinence, according to the firm.
In tests, nalmefene has been found to block the brain's ability to process pathological pleasures in 60 per cent of people addicted to gambling.
Nalmefene may be an option for patients who experience adverse side effects from naltrexone or who do not respond to that drug.
Lundbeck AS (CPH: LUN) said today it has completed the final study (ESENSE2) in the Phase III clinical programme for nalmefene in patients with alcohol dependence.
The efficacy of treatments targeting a reduction in alcohol use has been demonstrated only with nalmefene, in low-severity alcoholic patients (Van den Brink et al.
M2 PHARMA-January 3, 2011-Biotie says Lundbeck completes two Phase III studies with nalmefene in alcohol dependence(C)2011 M2 COMMUNICATIONS
Earlier today, Lundbeck said it has completed two of three pivotal phase III clinical trials with its product nalmefene for the treatment of alcohol dependence, which have shown positive results.
Although human studies have confirmed that naltrexone and another opiate antagonist, nalmefene, are both effective in preventing relapse in abstinent alcoholics (Schuckit 1996), the effects of opiate antagonists on stress-induced relapse have nor yet been investigated specifically in humans.
The decrease primarily reflects the completion of the Phase 3 clinical development program for SILENOR[TM] and the clinical trials of nalmefene for smoking cessation and the treatment of pathological gambling which were conducted during 2006.
JR had financial support for the submitted work from an unrestricted educational grant from Lundbeck; has received remuneration and travel expenses from Lundbeck for Board meetings in combination with Nalmefene, a pharmacological compound intended to treat alcohol dependence; no other relationships or activities that could appear to have influenced the submitted work.
Lundbeck annonced today that it has completed two of three pivotal Phase III clinical trials with its product nalmefene for the treatment of alcohol dependence, which have shown positive results.